| 1 | Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease显示文摘BACKGROUND Sodium glucose cotransporter-2 inhibitors(SGLT2-I)are the most recently approved drugs for type 2 diabetes(T2D).Recent clinical trials of these compounds reported beneficial cardiovascular(CV)and renal outcomes.A major cause of vascular dysfunction and CV disease in diabetes is hyperglycemia associated with inflammation and oxidative stress.Pre-clinical studies demonstrated that SGLT2-I reduce glucotoxicity and promote anti-inflammatory effects by lowering oxidative stress.AIM To investigate the effects of SGLT2-I on markers of oxidative stress,inflammation,liver steatosis,and fibrosis in patients of T2D with non-alcoholic fatty liver disease(NAFLD).METHODS We referred fifty-two consecutive outpatients treated with metformin monotherapy and exhibiting poor glycemic control to our centre.We introduced the outpatients to an SGLT2-I(dapagliflozin,empagliflozin,or canagliflozin;n=26)or a different hypoglycemic drug[other glucose-lowering drugs(OTHER),n=26].We evaluated circulating interleukins and serum hydroxynonenal(HNE)-or malondialdehyde(MDA)-protein adducts,fatty liver index(FLI),NAFLD fibrosis score,aspartate aminotransferase(AST)/alanine aminotransferase(ALT)ratio,AST-to-platelet-ratio index(APRI),and fibrosis-4 on the day before(T0)and following treatment for six months(T1).We also performed transient elastography at T0 and T1.RESULTS Add-on therapy resulted in improved glycemic control and reduced fasting blood glucose in both groups.Of note,following treatment for six months,a reduction of FLI and APRI,as well as of the FibroScan result,was reported in patients treated with SGLT2-I,but not in the OTHER group;furthermore,in the SGLT2-I group,we reported lower circulating levels of interleukin(IL)-1β,IL-6,tumor necrosis factor,vascular endothelial growth factor,and monocyte chemoattractant protein-1,and higher levels of IL-4 and IL-10.We did not observe any modification in circulating interleukins in the OTHER group.Finally,serum HNE-and MDA-protein adducts decreased significantly in SGLT2-I rather than OTHER patients and correlated with liver steatosis and fibrosis scores.CONCLUSION The present data indicate that treatment with SGLT2-I in patients with T2D and NAFLD is associated with improvement of liver steatosis and fibrosis markers and circulating pro-inflammatory and redox status,more than optimizing glycemic control. | Francesco Bellanti Aurelio Lo Buglio MichałDobrakowski Aleksandra Kasperczyk Sławomir Kasperczyk Palok Aich Shivaram P Singh Gaetano Serviddio Gianluigi Vendemiale | 2022 | World Journal of Gastroenterology2022，28，26： | 3 |
| 2 | A deeper understanding of the gut microbiota of different human races in search of disease specific microbial and metabolic biomarkers显示文摘Objective:Resident microorganisms live in dynamic harmony with their hosts to influence various physical and psychological health aspects.The majority of the resident microbes are found in the digestive tract,aka the gut of mammals.If and when perturbed,the composition of gut microbiota could jeopardize the physiological balance or homeostasis.In this article,we aim to establish how different diseases could be accompanied by notable changes in gut microbial composition and lend insight into microbial regulation of health.Methods:Literature search was done in PubMed using relevant keywords and summarized in tabular form as well as in narration.Results:We try to focus on the concept of microbial and metabolite biomarkers for diseases.We also try to capture the renewed perspective of good and harmful microorganisms in the context of host health.We have presented a comparative network analysis of microbial roles in select diseases.Recent findings also suggested that the growth of some traditionally disease-causing pathogenic microorganisms promotes health in other human communities.We have listed major taxa of gut microbes in communities worldwide,which signifies that gut microbiota can be healthy or harmful depending on the urbanization and ethnicity of the hosts.The traditional and current schools of thoughts are both limited by the technology of metagenomic studies;we have elucidated some of their shortcomings.Conclusion:Research in the field of gut microbiota must take into account the different populations and the changing narrative of healthy and harmful microbes. | Sohini Mukhopadhyay Tanya Pattnaik Palok Aich | 2022 | Microenvironment & Microecology Research2022，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员